miR-27a在妇科肿瘤中的研究进展  

Research progress of miR-27a in gynecological tumors

作　　者：李圃[1] 杜晓琴[2] LI Pu;DU Xiao-qin(Department of Gynecology,Tianjin Central Obstetrics and Gynecology Hospital,Tianjin 300100,China;Department of Science and Education,Tianjin Central Obstetrics and Gynecology Hospital,Tianjin 300100,China)

机构地区：[1]天津市中心妇产科医院普妇科,300100 [2]天津市中心妇产科医院科教科,300100

出　　处：《天津医药》2020年第5期455-459,共5页Tianjin Medical Journal

摘　　要：微小RNA(miRNA)是一类内源性的非编码小RNA,通常可通过特异性降解mRNA或抑制蛋白质的翻译,在转录后水平调控靶基因的表达,参与机体的多个生理或病理过程。miRNA可通过调节癌基因和抑癌基因的表达来参与肿瘤的发生发展,在不同类型的肿瘤中及肿瘤的不同发展阶段,miRNA分子的表达谱呈现不同的特征。其中,miR-27a定位于人类19号染色体,在子宫内膜癌、宫颈癌、卵巢癌等多种妇科肿瘤中异常表达。本文对miR-27a在子宫内膜癌、宫颈癌和卵巢癌中的作用及其临床应用进展进行综述,为开发新型的肿瘤分子标志物或靶向药物提供理论依据。MicroRNAs(miRNAs),a class of endogenous small non-coding RNAs,generally regulate gene expressions at post-transcriptional level through mRNA degradation or translation inhibition.miRNAs are involved in multiple physiological or pathological processes.miRNA can regulate the expression of oncogene and tumor suppressor gene to participate in the development of tumor.Different types or different stages of tumors show distinct miRNA expression profiles,which imply the potential applications of miRNAs.miR-27 a is located at human chromosome 19 and shows dysregulated expressions in endometrial cancer,ovarian cancer,cervical cancer and many other diseases.In this review,we summarized the research progress of miR-27 a in human gynecological tumors,providing novel insights on the development of tumor biomarkers or therapeutic agents.

关 键 词：miR-27a 妇科肿瘤 综述 

分 类 号：R737.3[医药卫生—肿瘤]